Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients

NCT00473824 is registered in ClinicalTrials.gov with ADMA Biologics, Inc. as lead sponsor.

NCT NCT00473824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00473824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplant Recipients
Lead sponsor
ADMA Biologics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2007
Completion date
February 28, 2009
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

evidence of liver transplantation, sequelae of viral hepatitis, transplantation infection